Načítá se...
Antiviral Efficacy of Pralatrexate against SARS-CoV-2
Novel coronavirus (SARS-CoV-2) has caused more than 100 million confirmed cases of human infectious disease (COVID-19) since December 2019 to paralyze our global community. However, only limited access has been allowed to COVID-19 vaccines and antiviral treatment options. Here, we report the efficac...
Uloženo v:
| Vydáno v: | Biomol Ther (Seoul) |
|---|---|
| Hlavní autoři: | , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
The Korean Society of Applied Pharmacology
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8094065/ https://ncbi.nlm.nih.gov/pubmed/33731494 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4062/biomolther.2021.032 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|